- Home
- CHD vs MRNA Comparison
CHD vs MRNA Comparison
Compare CHD & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHD | MRNA |
|---|---|---|
| Founded | 1846 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.4B | 21.6B |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CHD | MRNA |
|---|---|---|
| Price | $96.24 | $46.99 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 12 |
| Target Price | ★ $102.18 | $34.27 |
| AVG Volume (30 Days) | 1.8M | ★ 6.8M |
| Earning Date | 05-01-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.28% | N/A |
| EPS Growth | ★ 27.43 | 21.77 |
| EPS | ★ 0.91 | N/A |
| Revenue | $6,203,200,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $0.25 | $9.36 |
| Revenue Next Year | $3.65 | $15.43 |
| P/E Ratio | $105.02 | ★ N/A |
| Revenue Growth | 1.57 | ★ 4.29 |
| 52 Week Low | $81.33 | $22.28 |
| 52 Week High | $106.04 | $59.55 |
Technical Indicators
Market Signals| Indicator | CHD | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 53.98 | 43.88 |
| Support Level | $91.22 | $46.30 |
| Resistance Level | $96.62 | $55.36 |
| Average True Range (ATR) | 2.28 | 3.33 |
| MACD | 0.28 | -0.28 |
| Stochastic Oscillator | 80.69 | 9.92 |
Price Performance
Historical ComparisonAbout CHD Church & Dwight Company Inc.
Church & Dwight is the leading global producer of baking soda. Its portfolio extends beyond its legacy category to include laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its brands also include Batiste, OxiClean, Vitafusion, Hero, and TheraBreath, which, together with Arm & Hammer, account for around 70% of its annual sales and profits. Most recently, the firm added Touchland and its hand sanitizer business to its fold. Even as it works to expand its product reach, Church & Dwight still derives around 80% of its sales from its home market in the US.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.